Taburet A[au] - Search Results

Year	Number of Results
1979	5
1980	1
1982	1
1983	2
1984	2
1985	2
1986	2
1987	2
1989	5
1990	6
1991	4
1992	4
1993	6
1994	3
1995	3
1996	1
1998	3
1999	5
2000	4
2001	3
2002	2
2003	3
2004	5
2005	5
2006	6
2007	7
2008	4
2009	10
2010	9
2011	12
2012	7
2013	10
2014	9
2015	9
2016	5
2017	4
2018	4
2019	3
2020	3
2021	1
2022	0

1

Niveau de preuve du suivi thérapeutique pharmacologique du lopinavir.

Barrail-Tran A, Taburet AM, Poirier JM; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Barrail-Tran A, et al. Among authors: taburet am. Therapie. 2011 May-Jun;66(3):231-8. doi: 10.2515/therapie/2011034. Therapie. 2011. PMID: 27393203 French.

2

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM. Le Tiec C, et al. Among authors: taburet am. Clin Pharmacokinet. 2005;44(10):1035-50. doi: 10.2165/00003088-200544100-00003. Clin Pharmacokinet. 2005. PMID: 16176117 Review.

3

[Evidence-based therapeutic drug monitoring for indinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. Barrail-Tran A, et al. Among authors: taburet am. Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Therapie. 2011. PMID: 21819808 Review. French.

4

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Chauvin B, et al. Among authors: taburet am. Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. Clin Pharmacokinet. 2013. PMID: 23703578 Review.

5

Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.

Gelé T, Chéret A, Castro Gordon A, Nkam L, Furlan V, Pallier C, Becker PH, Catalan P, Goujard C, Taburet AM, Gasnault J, Gouget H, Barrail-Tran A. Gelé T, et al. Among authors: taburet am. J Antimicrob Chemother. 2021 Nov 12;76(12):3280-3285. doi: 10.1093/jac/dkab334. J Antimicrob Chemother. 2021. PMID: 34508640

6

Pharmacokinetic optimisation of asthma treatment.

Taburet AM, Schmit B. Taburet AM, et al. Clin Pharmacokinet. 1994 May;26(5):396-418. doi: 10.2165/00003088-199426050-00006. Clin Pharmacokinet. 1994. PMID: 7914480 Review.

7

The effect of respiratory disorders on clinical pharmacokinetic variables.

Taburet AM, Tollier C, Richard C. Taburet AM, et al. Clin Pharmacokinet. 1990 Dec;19(6):462-90. doi: 10.2165/00003088-199019060-00004. Clin Pharmacokinet. 1990. PMID: 2292169 Review.

8

[Antiretroviral agents in HIV-infected patients with cirrhosis].

Salmon-Céron D, Sogni P, Spiridon G, Taburet AM. Salmon-Céron D, et al. Among authors: taburet am. Presse Med. 2005 Jun 4;34(10 Suppl):1S45-52. Presse Med. 2005. PMID: 16025667 Review. French.

9

Drug interactions with antiviral drugs.

Taburet AM, Singlas E. Taburet AM, et al. Clin Pharmacokinet. 1996 May;30(5):385-401. doi: 10.2165/00003088-199630050-00005. Clin Pharmacokinet. 1996. PMID: 8743337 Review.

10

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.

Gelé T, Gouget H, Furlan V, Becker PH, Taburet AM, Lambotte O, Barrail-Tran A. Gelé T, et al. Among authors: taburet am. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e00895-20. doi: 10.1128/AAC.00895-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32868324 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results